Literature DB >> 33193822

What are acute NHS trusts in England doing to prevent the cross-border spread of carbapenem-resistant Enterobacteriaceae?

Sharon Mawdsley1.   

Abstract

BACKGROUND: Carbapenem-resistant Enterobacteriaceae (CRE) pose a significant threat to global public health as these organisms have the potential to cause infections which are easily spread and are associated with high mortality rates. AIM/
OBJECTIVE: The aim of this study was to establish which screening strategies acute NHS trusts in England have chosen to adopt and whether or not that strategy has prevented or is likely to prevent the cross-border spread of CRE.
METHODS: All acute NHS trusts in England were invited to participate in a multicentre quantitative study. Participants were asked to complete a questionnaire relating to their local CRE screening protocol. FINDINGS/
RESULTS: Of the 91 participating trusts, 83 (91.2%) adhere to Public Health England (2013) guidance. However, only 22 (24.2%) trusts have adopted the European Centre for Disease Prevention and Control (2016) recommendations. In total, 31 (34.1%) trusts reported incidences of person-to-person transmission, of which 45.2% were related to foreign travel. Furthermore, 31 (34.1%) trusts reported that patients who have had an admission to a hospital in the UK not known to have a high prevalence of healthcare-associated CRE in the last 12 months had screened positive. DISCUSSION: This study has demonstrated that inter-hospital transmission is as much of a concern as cross-border spread. Mandatory participation in enhanced surveillance could provide PHE with the epidemiological evidence required to support this stance and help to develop new national guidance.
© The Author(s) 2020.

Entities:  

Keywords:  Epidemiology; Gram-negative bacteria; healthcare-associated infections

Year:  2020        PMID: 33193822      PMCID: PMC7607406          DOI: 10.1177/1757177420935633

Source DB:  PubMed          Journal:  J Infect Prev        ISSN: 1757-1782


  12 in total

Review 1.  Controversies in guidelines for the control of multidrug-resistant Gram-negative bacteria in EU countries.

Authors:  J A Otter; N T Mutters; E Tacconelli; A Gikas; A H Holmes
Journal:  Clin Microbiol Infect       Date:  2015-10-03       Impact factor: 8.067

2.  Enhancing surveys of health care professionals: a meta-analysis of techniques to improve response.

Authors:  Young Ik Cho; Timothy P Johnson; Jonathan B Vangeest
Journal:  Eval Health Prof       Date:  2013-09       Impact factor: 2.651

3.  High Rate of Acquisition but Short Duration of Carriage of Multidrug-Resistant Enterobacteriaceae After Travel to the Tropics.

Authors:  Etienne Ruppé; Laurence Armand-Lefèvre; Candice Estellat; Paul-Henri Consigny; Assiya El Mniai; Yacine Boussadia; Catherine Goujon; Pascal Ralaimazava; Pauline Campa; Pierre-Marie Girard; Benjamin Wyplosz; Daniel Vittecoq; Olivier Bouchaud; Guillaume Le Loup; Gilles Pialoux; Marion Perrier; Ingrid Wieder; Nabila Moussa; Marina Esposito-Farèse; Isabelle Hoffmann; Bruno Coignard; Jean-Christophe Lucet; Antoine Andremont; Sophie Matheron
Journal:  Clin Infect Dis       Date:  2015-04-22       Impact factor: 9.079

4.  Screening suspected cases for carbapenemase-producing Enterobacteriaceae, inclusion criteria and demand.

Authors:  Vella Venanzio; Myriam Gharbi; Luke S P Moore; Julie Robotham; Frances Davies; Eimear Brannigan; Tracey Galletly; Alison H Holmes
Journal:  J Infect       Date:  2015-06-10       Impact factor: 6.072

5.  Link between carbapenemase-producing Enterobacteria carriage and cross-border exchanges: eight-year surveillance in a large French multihospitals institution.

Authors:  Sandra Fournier; Margaux Lepainteur; Najiby Kassis-Chikhani; Michele Huang; Christian Brun-Buisson; Vincent Jarlier
Journal:  J Travel Med       Date:  2012-08-01       Impact factor: 8.490

6.  Carbapenemase-producing Acinetobacter baumannii: An outbreak report with special highlights on economic burden.

Authors:  J Gagnaire; A Gagneux-Brunon; A Pouvaret; F Grattard; A Carricajo; H Favier; A Mattei; B Pozzetto; C Nuti; F Lucht; P Berthelot; E Botelho-Nevers
Journal:  Med Mal Infect       Date:  2017-03-23       Impact factor: 2.152

7.  Universal hospital admission screening for carbapenemase-producing organisms in a low-prevalence setting.

Authors:  Jonathan A Otter; Eleonora Dyakova; Karen N Bisnauthsing; Antonio Querol-Rubiera; Amita Patel; Chioma Ahanonu; Olga Tosas Auguet; Jonathan D Edgeworth; Simon D Goldenberg
Journal:  J Antimicrob Chemother       Date:  2016-08-11       Impact factor: 5.790

8.  Outbreaks of colistin-resistant and colistin-susceptible KPC-producing Klebsiella pneumoniae in a Brazilian intensive care unit.

Authors:  I Rossi Gonçalves; M L Ferreira; B F Araujo; P A Campos; S Royer; D W F Batistão; L P Souza; C S Brito; J E Urzedo; P P Gontijo-Filho; R M Ribas
Journal:  J Hosp Infect       Date:  2016-08-26       Impact factor: 3.926

9.  Carbapenemase-producing Klebsiella pneumoniae in the Czech Republic in 2011.

Authors:  J Hrabák; C C Papagiannitsis; V Študentová; V Jakubu; M Fridrichová; H Zemlickova
Journal:  Euro Surveill       Date:  2013-11-07

10.  The carbapenem-resistant Enterobacteriaceae threat is growing: NDM-1 epidemic at a training hospital in Turkey.

Authors:  Oguz Karabay; Mustafa Altindis; Mehmet Koroglu; Onur Karatuna; Özlem Akkaya Aydemir; Ali Fuat Erdem
Journal:  Ann Clin Microbiol Antimicrob       Date:  2016-02-09       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.